Molecular determinants of resistance to antiandrogen therapy
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Using microarray-based profiling of isogenic prostate cancer xenograft models, we found that a modest increase in androgen receptor mRNA was the only change consistently associated with the development of resistance to antiandrogen therapy. This increase in androgen receptor mRNA and protein was both necessary and sufficient to convert prostate cancer growth from a hormone-sensitive to a hormone-refractory stage, and was dependent on a functional ligand-binding domain. Androgen receptor antagonists showed agonistic activity in cells with increased androgen receptor levels; this antagonist-agonist conversion was associated with alterations in the recruitment of coactivators and corepressors to the promoters of androgen receptor target genes. Increased levels of androgen receptor confer resistance to antiandrogens by amplifying signal output from low levels of residual ligand, and by altering the normal response to antagonists. These findings provide insight toward the design of new antiandrogens.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“FKBP51 overexpression was not detected in a previous microarray analysis of the LAPC-4 xenografts (3).”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“which is known to promote AI-type growth in human prostate cancer models (3)”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“AR overexpression is a signature of AI disease, and forcing AR expression in model systems is sufficient to generate AI growth and responsiveness to antiandrogens (3).”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“AR overexpression is a signature of AI disease, and forcing AR expression in model systems is sufficient to generate AI growth and responsiveness to antiandrogens (3).”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“Several studies have provided evidence that this disease progression may be due in part to intratumoral synthesis of androgens, with castration-resistant prostate-cancer cells overexpressing the enzymes required for androgen biosynthesis.”
From Abiraterone and Increased Survival in Metastatic Prostate Cancer (2011) · cites this paper as [35]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261 · cited 1×
“Because xenograft-specific expression signatures are likely to obscure the gene expression changes responsible for the transition from hormone-sensitive to hormone-refractory state”
BackgroundShiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., & Greene, G. L. (1998) · Cell · doi:10.1016/s0092-8674(00)81717-1 · Cited by 2,729 · cited 1×
“Because steroid receptor–antagonist complexes adopt a variety of conformation”
BackgroundThe development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326 · cited 1×
“The postulated mechanisms to explain resistance to hormone therapy can be separated into three general categorie”
BackgroundThe coregulator exchange in transcriptional functions of nuclear receptors
Glass, C. K., & Rosenfeld, M. G. (2000) · Genes & Development · doi:10.1101/gad.14.2.121 · Cited by 2,233
Self-citationActivation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., et al. (1995) · Science · doi:10.1126/science.270.5241.1491 · Cited by 1,964 · cited 1×
“The kinases and substrates responsible for androgen receptor activation in this setting are unknown, but it is presumed to occur through downstream phosphorylation of androgen receptor–associated proteins or through the androgen receptor itself, analogous to the estrogen recepto”
BackgroundLNCaP model of human prostatic carcinoma.
Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H. E., Chu, T. M., MIRAND, E. A., & Murphy, G. P. (1983) · PubMed · Cited by 1,789
In vivo amplification of the androgen receptor gene and progression of human prostate cancer
Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., & Kallioniemi, O.-P. (1995) · Nature Genetics · doi:10.1038/ng0495-401 · Cited by 1,484
Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer
Taplin, M.-E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., & Balk, S. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505253322101 · Cited by 1,253
Molecular Determinants for the Tissue Specificity of SERMs
Shang, Y., & Brown, M. (2002) · Science · doi:10.1126/science.1068537 · Cited by 1,146 · cited 1×
“Previous work has shown that the agonist-versus-antagonist response of nuclear receptors, such as the estrogen receptor, is altered by increased expression of coactivators (such as SRC-1) or by decreased expression of corepressors (such as NCoR”
BackgroundNongenotropic, Sex-Nonspecific Signaling through the Estrogen or Androgen Receptors
Kousteni, S., Bellido, T., Plotkin, L. I., O'Brien, C. A., Bodenner, D. L., Han, L., Han, K., DiGregorio, G. B., Katzenellenbogen, J. A., Katzenellenbogen, B. S., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00268-9 · Cited by 1,113
Cited by
Items 401–500 of 1,002
Berberine Suppresses Androgen Receptor Signaling in Prostate Cancer
Li, J., Cao, B., Liu, X., Fu, X., Xiong, Z., Chen, L., Sartor, O. A., Dong, Y., & Zhang, H. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0985 · Cited by 108
“Laboratory studies indicate that AR overexpression is necessary and sufficient to induce CRPC in a xenograft model (5).”
BackgroundAsim, M., Siddiqui, I. A., Hafeez, B. B., Baniahmad, A., & Mukhtar, H. (2008) · Oncogene · doi:10.1038/sj.onc.1211016 · Cited by 101
Kwegyir-Afful, A. K., Ramalingam, S., Purushottamachar, P., Ramamurthy, V. P., & Njar, V. C. O. (2015) · Oncotarget · doi:10.18632/oncotarget.4578 · Cited by 98
“Overexpression of fAR and AR-Vs is implicated in resistance to current approved therapy in HSPC and CRPC [11, 12].”
BackgroundInfluentialGleave, M. E., & Miyake, H. (2005) · World Journal of Urology · doi:10.1007/s00345-004-0474-0 · Cited by 112
“Progression to androgen independence is a complex process involving variable combinations of clonal selection [5], adaptive upregulation of anti-apoptotic survival genes [6, 7, 8, 9, 10], androgen receptor (AR) transactivation in the absence of androgen from mutations or increased levels of co-activators [11, 12] and…”
BackgroundShiota, M., Yokomizo, A., Masubuchi, D., Tada, Y., Inokuchi, J., Eto, M., Uchiumi, T., Fujimoto, N., & Naito, S. (2010) · The Prostate · doi:10.1002/pros.21088 · Cited by 101
Li, Y., Wang, L., Zhang, M., Melamed, J., Liu, X., Reiter, R. E., Wei, J., Peng, Y., Zou, X., Pellicer, À., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3380 · Cited by 111
“The AR expressing androgen-independent prostate cancer cells can grow in the absence of androgen, however, they grow faster in the presence of androgen (32).”
Terada, N., Shimizu, Y., Kamba, T., Inoue, T., Maeno, A., Kobayashi, T., Nakamura, E., Kamoto, T., Kanaji, T., Maruyama, T., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2984 · Cited by 101
“of androgens, induced by increased expression of the AR itself (10).”
BackgroundSun, T., Yang, M., Chen, S., Balk, S. P., Pomerantz, M. M., Hsieh, C.-L., Brown, M. A., Lee, G. M., & Kantoff, P. W. (2011) · The Prostate · doi:10.1002/pros.22456 · Cited by 106
Rathkopf, D. E., Smith, M. R., Ryan, C. J., Berry, W. R., Shore, N. D., Liu, G., Higano, C. S., Alumkal, J. J., Hauke, R., Tutrone, R. F., Jr., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx283 · Cited by 102
Sun, M., Geng, D., Li, S., Chen, Z., & Zhao, W. (2017) · Biological Chemistry · doi:10.1515/hsz-2017-0255 · Cited by 100
Mechanism of Androgen Receptor Antagonism by Bicalutamide in the Treatment of Prostate Cancer
Osguthorpe, D. J., & Hagler, A. T. (2011) · Biochemistry · doi:10.1021/bi102059z · Cited by 108
Androgen mediated regulation and functional implications of FKBP51 expression in prostate cancer
FEBBO, P. G., LOWENBERG, M., THORNER, A. R., BROWN, M., LODA, M., & GOLUB, T. R. (2005) · Journal of Urology · doi:10.1097/01.ju.0000155845.44729.ba · Cited by 99
Robinson, J. L. L., Hickey, T. E., Warren, A. Y., Vowler, S. L., Carroll, T., Lamb, A. D., Papoutsoglou, N., Neal, D. E., Tilley, W. D., & Carroll, J. S. (2014) · Oncogene · doi:10.1038/onc.2013.508 · Cited by 101
“Documented methods for circumvention of ADT include AR gene amplification, acquisition of mutations, genomic rearrangements and alternative splicing of AR (2, 5-8).”
MethodSarkar, S., Brautigan, D. L., Parsons, S. J., & Larner, J. M. (2012) · Oncogene · doi:10.1038/onc.2012.561 · Cited by 99
Liu, Y., Majumder, S., McCall, W., Sartor, C. I., Mohler, J. L., Gregory, C. W., Earp, H. S., & Whang, Y. E. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4292 · Cited by 101
Forootan, F. S., Forootan, S. S., Gou, X., Yang, J. K., Liu, B., Chen, D., Fayi, M. S. A., Al-Jameel, W. H., Rudland, P. S., Hussain, S. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6975 · Cited by 103
“Currently several mechanisms have been hypothesized [20]; the most common one is the AR sensitivity amplification theory [37, 38] which proposed that when deprived of androgen supply in the initial round of therapy, some cells try to maximise their .”
Trinchet, J. (2004) · Hepatology · doi:10.1002/hep.20474 · Cited by 98
Deubiquitinating Enzyme Usp12 Is a Novel Co-activator of the Androgen Receptor
McClurg, U. L., Harle, V. J., Coffey, K., Darby, S., Ramsey, H., O’Neill, D. J., Logan, I. R., Gaughan, L., & Robson, C. N. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.485912 · Cited by 98
“Similarly, AR overexpression in PCa xenograft in castrate animals still enhanced cancer growth (4).”
BackgroundKogan, I., Goldfinger, N., Milyavsky, M., Cohen, M., Shats, I., Dobler, G., Klocker, H., Wasylyk, B., Völler, M., Aalders, T. W., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2183 · Cited by 100
“hormone therapy eventually fails, leading to the development of hormone-refractory, drug-resistant malignancy (2).”
Androgen regulation of prostate cancer: Where are we now?
Corona, G., Baldi, E., & Maggi, M. (2011) · Journal of Endocrinological Investigation · doi:10.1007/bf03347072 · Cited by 108
Migliaccio, A., Varricchio, L., de Falco, A., Castoria, G., Arra, C., Yamaguchi, H., Ciociola, A., Lombardi, M., Stasio, R. D., Barbieri, A., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210487 · Cited by 98
“An increased level of AR could sensitize cancers to low levels of residual androgens, and antiandrogens could promote androgen activation rather than inhibition (Chen et al., 2004).”
BackgroundLong-range activation of FKBP51 transcription by the androgen receptor via distal intronic enhancers
Makkonen, H., Kauhanen, M., Paakinaho, V., Jääskeläinen, T., & Palvimo, J. J. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp352 · Cited by 97
“Since increased AR protein levels have been reported to convert antiandrogens, such as bicalutamide, to agonists (35), it was of interest to investigate whether the difference in the amount of AR between VCaP and LNCaP cells is manifested in a differential response to the pure antagonist bicalutamide (BIC).”
BackgroundWhen the chains do not break: the role of USP10 in physiology and pathology
Bhattacharya, U., Neizer‐Ashun, F., Mukherjee, P., & Bhattacharya, R. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03246-7 · Cited by 108
Zhang, Y., Wang, X.-W., Jelovac, D., Nakanishi, T., Yu, M.-H., Akinmade, D., Goloubeva, O., Ross, D. D., Brodie, A., & Hamburger, A. W. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503829102 · Cited by 98
Hååg, P., Frauscher, F., Gradl, J., Seitz, A., Schäfer, G., Lindner, J. R., Klibanov, A. L., Bartsch, G. C., Klocker, H., & Eder, I. E. (2006) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2006.09.027 · Cited by 96
Expression of androgen receptor splice variants in clinical breast cancers
Hickey, T. E., Irvine, C. M., Dvinge, H., Tarulli, G. A., Hanson, A. R., Ryan, N. K., Pickering, M. A., Birrell, S. N., Hu, D. G., Mackenzie, P. I., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6296 · Cited by 102
“Androgen signaling in the “castrate” environment is often mediated by direct changes to AR, including upregulation of its expression [17], amplification of the AR gene [18, 19] and mutations that result in aberrantly active receptors [18, 20–25].”
Inhibition of USP14 enhances the sensitivity of breast cancer to enzalutamide
Xia, X., Huang, C., Liao, Y., Liu, Y., He, J., Guo, Z., Jiang, L., Wang, X., Liu, J., & Huang, H. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1227-7 · Cited by 97
Mahajan, K. N., Coppola, D., Rawal, B., Chen, Y. A., Lawrence, H. R., Engelman, R. W., Lawrence, N. J., & Mahajan, N. P. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.357384 · Cited by 101
Dai, Y., Ngo, D., Forman, L. W., Qin, D. C., Jacob, J., & Faller, D. V. (2007) · Molecular Endocrinology · doi:10.1210/me.2006-0467 · Cited by 96
Chen, L., Meng, S., Wang, H., Bali, P., Bai, W., Li, B., Atadja, P. W., Bhalla, K. N., & Wu, J. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0287 · Cited by 99
“Accumulated evidence has shown that a major mechanism for progression to hormone-refractory (androgen independent) prostate cancer is the reactivation of androgen receptor (1, 3, 42).”
BackgroundInfluentialAnnala, M., Taavitsainen, S., Khalaf, D. J., Vandekerkhove, G. R., Beja, K., Sipola, J., Warner, E. W., Herberts, C., Wong, A., Fu, S. Y. F., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1625 · Cited by 106
“Because an increased AR copy number can result in elevated AR protein expression and greater ligand sensitivity (31), populations with higher AR copy number may have greater fitness during treatment.”
BackgroundLitvinov, I. V., Antony, L., Dalrymple, S. L., Becker, R. E., Cheng, L., & Isaacs, J. T. (2006) · The Prostate · doi:10.1002/pros.20483 · Cited by 97
“Previous studies documented that in type-II ADI prostate cancers AR can engage antagonists such as bicalutamide (casodex) as agonists to promote tumor growth [48].”
BackgroundConsideration of breast cancer subtype in targeting the androgen receptor
Venema, C. M., Bense, R. D., Steenbruggen, T. G., Nienhuis, H. H., Qiu, S.-Q., van Kruchten, M., Brown, M. A., Tamimi, R. M., Hospers, G. A. P., Schroder, C. P., et al. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.005 · Cited by 96
“Mechanisms that may be related to resistance to AR-targeted therapies in metastatic prostate cancer include amplification or overexpression of AR, ligand-independent activation, overexpression of coactivators, and the expression of active AR splice variants (Chen et al., 2004; Fujimoto, Mizokami, Harada, & Matsumoto,…”
BackgroundHepatitis C Virus Core Protein Augments Androgen Receptor-Mediated Signaling
Kanda, T., Steele, R., Ray, R., & Ray, R. B. (2008) · Journal of Virology · doi:10.1128/jvi.01300-08 · Cited by 101
“The transcriptional activation function of AR is not only essential for normal sexual development in men but is also implicated in the progression of cancer (9).”
BackgroundRegulation of androgen receptor signaling in prostate cancer
Dehm, S. M., & Tindall, D. J. (2005) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.5.1.63 · Cited by 94
Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours
Čulig, Z., Steiner, H., Bartsch, G., & Hobisch, A. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.00775a · Cited by 105
Castration-resistant prostate cancer: Targeting androgen metabolic pathways in recurrent disease
Mostaghel, E. A., Montgomery, B., & Nelson, P. S. (2009) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2009.03.016 · Cited by 101
“, prostate cancer growth in “castrate” animal models nduced by AR-overexpression is still ligand dependent [5].”
InfluentialLai, K., Huang, C.-K., Chang, Y., Chung, C., Yamashita, S., Li, L., Lee, S. O., Yeh, S., & Chang, C. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.10.029 · Cited by 98
Shepherding AKT and androgen receptor by Ack1 tyrosine kinase.
Mahajan, K., & Mahajan, N. P. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22162 · Cited by 92
“AR plays a crucial role in the development of advanced metastatic prostate cancer also known as androgen independent prostate cancer or AIPC (Grossmann et al., 2001; Chen et al., 2004).”
BackgroundDebes, J. D., Comuzzi, B., Schmidt, L. J., Dehm, S. M., Culig, Z., & Tindall, D. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2837 · Cited by 92
“Indeed, the androgen receptor is important for the proliferation of prostate cancer cells and is expressed after progression from androgendependent to -independent disease (4, 5).”
BackgroundAndrogen Receptor Tumor Suppressor Function Is Mediated by Recruitment of Retinoblastoma Protein
Gao, S., Gao, Y., He, H. H., Han, D. G., Han, W., Avery, A., Macoska, J. A., Liu, X., Chen, S., Ma, F., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.064 · Cited by 101
“Basal expression of each DNA replication gene examined was increased in LN-AR cells (Figure 4G), which is consistent with increased basal AR activity and decreased dependence on exogenous androgens for proliferation (Chen et al., 2004).”
BackgroundCellular rewiring in lethal prostate cancer: the architect of drug resistance
Carceles‐Cordon, M., Kelly, W. K., Gomella, L. G., Knudsen, K. E., Rodríguez-Bravo, V., & Domenech, J. M. D. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-0298-8 · Cited by 101
Duff, J., & McEwan, I. J. (2005) · Molecular Endocrinology · doi:10.1210/me.2005-0231 · Cited by 92
“However, recently Sawyers and co-workers (44) demonstrated that in a prostate cancer xenograft model, increasing the AR mRNA/protein level was sufficient to produce a hormone-refractory state and convert antagonists to agonists.”
BackgroundChen, X., Li, Q., Liu, X., Liu, C., Liu, R., Rycaj, K., Zhang, D., Liu, B., Jeter, C. R., Calhoun‐Davis, T., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2956 · Cited by 92
The Human PC346 Xenograft and Cell Line Panel: A Model System for Prostate Cancer Progression
Marques, R. B., van Weerden, W. M., Erkens‐Schulze, S., de Ridder, C. M., Bangma, C. H., Trapman, J., & Jenster, G. W. (2006) · European Urology · doi:10.1016/j.eururo.2005.12.035 · Cited by 100
“Some researchers have proposed that higher receptor levels could lead to sensitization to residual androgen concentrations and broadened ligand-specificity [49] or to constitutive ligand-independent activation [50].”
BackgroundMitsiades, N. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4414 · Cited by 97
AR and PI3K/AKT in Prostate Cancer: A Tale of Two Interconnected Pathways
Tortorella, E., Giantulli, S., Sciarra, A., & Silvestri, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032046 · Cited by 109
“Elevated AR protein levels were also linked to CRPC [64].”
BackgroundYang, Y., Ikezoe, T., Takeuchi, T., Adachi, Y., Ohtsuki, Y., Takeuchi, S., Koeffler, H. P., & Taguchi, H. (2005) · Cancer Science · doi:10.1111/j.1349-7006.2005.00063.x · Cited by 94
Mechanisms of Androgen Receptor Activation in Castration-Resistant Prostate Cancer
Sharifi, N. (2013) · Endocrinology · doi:10.1210/en.2013-1466 · Cited by 110
“activity of AR antagonists to AR agonist activity (18).”
BackgroundPeterson, T. J., Karmakar, S., Pace, M. C., Gao, T., & Smith, C. L. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00237-07 · Cited by 91
“Using chromatin immunoprecipitation (ChIP) assays, another study demonstrated concurrent binding of N-CoR, the coactivators SRC-1 and PCAF, and RNA polymerase II to the promoter of the androgen-regulated prostate-specific antigen gene in antiandrogen-resistant LNCaP prostate cancer cells treated with the AR antagonist…”
MethodCrosstalking between Androgen and PI3K/AKT Signaling Pathways in Prostate Cancer Cells
Lee, S. H., Johnson, D. T., Luong, R. H., & Sun, Z. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.607846 · Cited by 102
“2 The abbreviations used are: AR, androgen receptor; mPIN, murine prostatic intraepithelial neoplasia; DHT, 5 -dihydrotestosterone; ADT, androgen ablation therapy; CRPC, castration-resistant prostate cancer; PTEN, phosphatase and tensin homolog chromosome 10.”
BackgroundInfluentialDonovan, M. J., Hamann, S., Clayton, M., Khan, F. M., Sapir, M., Bayer‐Zubek, V., Fernández, G., Mesa‐Tejada, R., Teverovskiy, M., Reuter, V. E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.3155 · Cited by 90
Ryan, C. J., Halabi, S., Ou, S.-S., Vogelzang, N. J., Kantoff, P., Small, E. J., & for the Cancer and Leukemia Group B (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2344 · Cited by 91
“(grant CA33601) (3) Dartmouth Med School-Norris Cotton Cancer Center,”
BackgroundInfluentialCurrent Insights into Long Non-Coding RNAs (LncRNAs) in Prostate Cancer
Smolle, M. A., Bauernhofer, T., Pummer, K., Călin, G. A., & Pichler, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020473 · Cited by 97
“The ineffectiveness of conventional ADT in these mCRPC is a result of androgen-independent activation of the AR and its downstream pathways [14].”
BackgroundCarcinogenesis, cancer therapy and chemoprevention
Blagosklonny, M. V. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401610 · Cited by 104
“Even further, inhibitors of androgen receptor may stimulate rather than inhibit resistant cancer cell.(81) In differentiated thyroid cancer, therapy with”
BackgroundTargeting the androgen receptor in prostate and breast cancer: several new agents in development
Proverbs-Singh, T. A., Feldman, J. L., Morris, M. J., Autio, K. A., & Traina, T. A. (2015) · Endocrine Related Cancer · doi:10.1530/erc-14-0543 · Cited by 97
“…state in PCa through AR overexpression or gene amplification, increased intratumoral androgen synthesis, aberrant AR expression (either by mutation or splice variants), and activation of alternative pathways (Ford et al. 2003, Chen et al. 2004, Stanbrough et al. 2006, Montgomery et al. 2008).”
BackgroundLncRNA GAS5 Inhibits Cellular Proliferation by Targeting P27Kip1
Luo, G., Liu, D., Huang, C., Wang, M., Xiao, X., Zeng, F., Wang, L., & Jiang, G. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0331 · Cited by 93
Wnt/Beta-Catenin Signaling and Prostate Cancer Therapy Resistance
Yeh, Y. A., Guo, Q., Connelly, Z. M., Cheng, S., Yang, S., Prieto‐Domínguez, N., & Yu, X. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-32656-2_16 · Cited by 99
Niu, Y., Yeh, S., Miyamoto, H., Li, G., Altuwaijri, S., Yuan, J., Han, R., Ma, T., Kuo, H.-C., & Chang, C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6507 · Cited by 90
“But in the hormone-refractory cancer, although AR still exists (14), the abnormal PSA elevation may have little linkage with AR status.”
BackgroundResultWu, C., Hsieh, C., Lin, C., Chen, W., Hong, J., & Chen, M. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0916-x · Cited by 93
Yang, Y., Jia, D., Kim, H., Elmageed, Z. Y. A., Datta, A., Davis, R., Srivastav, S., Moroz, K., Crawford, B. E., Moparty, K., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1606 · Cited by 92
“Introduction Aberrant expression of androgen receptor (AR) is implicated in initiation and development of castration-resistant prostate cancer (1).”
BackgroundLu, M., Yang, L., Li, R., Rodrigues, D. N., Crespo, M., Hsieh, J., Tilley, W. D., Bono, J. S. D., Selth, L. A., & Raj, G. V. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2169 · Cited by 95
Blockade of testicular and adrenal androgens in prostate cancer treatment
Labrie, F. (2011) · Nature Reviews Urology · doi:10.1038/nrurol.2010.231 · Cited by 104
Intrinsic disorder in the androgen receptor: identification, characterisation and drugability
McEwan, I. J. (2011) · Molecular BioSystems · doi:10.1039/c1mb05249g · Cited by 86
A magic drug target: Androgen receptor
Li, D., Zhou, W., Pang, J., Tang, Q., Zhong, B., Shen, C., Li, X., & Hou, T. (2018) · Medicinal Research Reviews · doi:10.1002/med.21558 · Cited by 91
“Hundreds of genes, such as KLK3 (encoding prostate‐specific antigen [PSA]), KLK2, FKBP5, etc, can be regulated by AR.(5) Maintaining the whole regulation process on a right track to keep a proper homeostasis of the genes’ expression is crucial for the growth, development, and health status of human bodies.”
BackgroundInfluentialInternational Journal of Scientific Research
Baruah, A., Das, S., Dutta, A., Das, B., Sharma, T., & Hazarika, M. (2025) · International Journal of Scientific Research · doi:10.15373/22778179 · Cited by 89
Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity.
Mahajan, K., Challa, S., Coppola, D., Lawrence, H., Luo, Y., Gevariya, H., Zhu, W., Chen, Y. A., Lawrence, N. J., & Mahajan, N. P. (2010) · The Prostate · doi:10.1002/pros.21163 · Cited by 86
“As AR activity acquires resistance to high doses of the antagonists, ARregulated genes become overexpressed in CRPC [8,9].”
BackgroundMartin, S. K., Pu, H., Penticuff, J. C., Cao, Z., Horbinski, C., & Kyprianou, N. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2078 · Cited by 85
“Recent antiandrogen therapies such as Abiraterone Acetate and Enzalutamide although effectively target the androgen signaling axis (4-6), due to the addiction of CRPC cells to AR signaling and constitutively active AR splice variants, resistance develops and disease recurs (7-9).”
BackgroundAndrogen receptor targeted therapies in castration‐resistant prostate cancer: Bench to clinic
Imamura, Y., & Sadar, M. D. (2016) · International Journal of Urology · doi:10.1111/iju.13137 · Cited by 86
The microRNA signatures: aberrantly expressed miRNAs in prostate cancer
Sharma, N., & Baruah, M. M. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-1910-8 · Cited by 93
Rathkopf, D. E., Patel, M. R., Choudhury, A. D., Rasco, D. W., Lakhani, N. J., Hawley, J. E., Srinivas, S., Aparicio, A. M., Narayan, V., Runcie, K. D., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.09.005 · Cited by 97
Buchanan, G., Ricciardelli, C., Harris, J. M., Prescott, J., Yu, Z. C.-L., Li, J., Butler, L. M., Marshall, V. R., Scher, H. I., Gerald, W. L., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1646 · Cited by 94
“The increased AR level often observed in metastatic PCa, and recently shown to be predictive of progression in localized disease (2, 27, 40 ), might overwhelm the capacity of limiting cellular aSGT to (a) ensure AR conformational quality and appropriate cellular localization, (b) buffer basal and ligand-independent re…”
BackgroundYamaoka, M., Hara, T., & Kusaka, M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0255 · Cited by 94
“resistance have been proposed: (i) AR activation by androgens converted from adrenal androgens or synthesized intratumorally via the de novo route (8,9); (ii) hypersensitivity of ARs due to overexpression of AR proteins and/or changes in cofactor expression levels (10,11); (iii) promiscuous activation of AR signaling…”
Hodgson, M. C., Astapova, I. I., Hollenberg, A. N., & Balk, S. P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0617 · Cited by 92
“expression can enhance the growth of prostate cancer xenografts in castrated mice and has been reported to enhance the agonist activity of the AR antagonist bicalutamide (10).”
BackgroundInfluentialAndrogen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival
Sun, C., Shi, Y., Xu, L., Nageswararao, C., Davis, L., Segawa, T., Dobi, A. L., McLeod, D. G. R., & Srivastava, S. K. (2006) · Oncogene · doi:10.1038/sj.onc.1209424 · Cited by 86
“Furthermore, these results lead to the alteration of AR transcription factor functions (Veldscholte et al., 1990; Culig et al., 2000; Chen et al., 2004; Taplin and Balk, 2004).”
BackgroundResultInfluentialSex hormones and prostate cancer
Auchus, R. J., & Sharifi, N. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-051418-060357 · Cited by 85
Androgen and the elaborate courtship behavior of a tropical lekking bird
Fusani, L., Day, L. B., Canoine, V., Reinemann, D., Hernandez, E., & Schlinger, B. A. (2006) · Hormones and Behavior · doi:10.1016/j.yhbeh.2006.08.005 · Cited by 85
“The following increase in courtship behavior above control levels might have resulted from an increased sensitivity to androgen because of the up-regulation of AR expression described previously after anti-androgen treatment (Chen et al., 2004).”
BackgroundVersatile pathway-centric approach based on high-throughput sequencing to anticancer drug discovery
Li, H., Zhou, H., Wang, D., Qiu, J., Zhou, Y., Li, X., Rosenfeld, M. G., Ding, S., & Fu, X.-D. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200305109 · Cited by 86
“We have initially applied this technology on a prostate cancer cell (LNCaP) model to identifying small molecules that can block the androgen receptor (AR)-mediated gene expression, because AR overexpression has been linked to prostate cancer progression to androgen-refractory, incurable tumors (8, 9).”
MethodSelf-citationAndrogen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP
Rokhlin, O. W., Taghiyev, A. F., Guseva, N. V., Glover, R. A., Chumakov, P. M., Kravchenko, J. E., & Cohen, M. B. (2005) · Oncogene · doi:10.1038/sj.onc.1208833 · Cited by 98
Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer
Chuu, C., Kokontis, J. M., Hiipakka, R. A., Fukuchi, J., Lin, H., Lin, C., Huo, C., & Su, L. (2011) · Journal of Biomedical Science · doi:10.1186/1423-0127-18-63 · Cited by 90
“Increase in AR mRNA and protein is both necessary and sufficient to convert prostate cancer growth from a hormone-sensitive to a hormone-refractory stage, and is dependent on a functional ligand-binding domain [16,17].”
BackgroundCai, L., Tsai, Y., Wang, P., Wang, J., Li, D., Fan, H., Zhao, Y., Bareja, R., Lu, R., Wilson, E. M., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.08.029 · Cited by 96
“However, therapy resistance develops, ultimately owing to various mechanisms, including AR gene amplification or mutation (Chen et al., 2004; Gottlieb et al., 2012; Taylor et al., 2010; Visakorpi et al., 1995); intratumoral androgen production (Montgomery et al., 2008); expression of AR splice…”
Androgen receptor decoy molecules block the growth of prostate cancer.
Quayle, S. N., Mawji, N. R., Wang, J., & Sadar, M. D. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606718104 · Cited by 84
Crona, D. J., Milowsky, M., & Whang, Y. E. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.256 · Cited by 87
“Moreover, at the molecular level, first-generation antiandrogens have actually been shown to have AR agonist activity in CRPC cells where AR protein has been overexpressed.(23,24) In response to the knowledge that CRPC remains dependent on androgens and AR signaling, as well as the shortcomings of firstgeneration anti…”
BackgroundZhao, J., Ning, S., Lou, W., Yang, J. C., Armstrong, C. M., Lombard, A. P., D'Abronzo, L. S., Evans, C. P., Gao, A. C., & Liu, C. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0015 · Cited by 86
“Following the discovery that CRPC patients remain dependent on androgen receptor (AR) signaling (2-5), targeting AR became the major strategy for the treatment of CRPC.”
Gat, Y., Gornish, M., Heiblum, M., & Joshua, S. (2008) · Andrologia · doi:10.1111/j.1439-0272.2008.00883.x · Cited by 87
“…during anti-androgen therapy (Mostaghel et al., 2007); why castration-resistant prostate cancer develops (androgen-independent prostate cancer) (Chen et al., 2004; Isaacs & Isaacs, 2004); why prostate cancer is one of the slowest among cancer diseases where most patients with localised…”
BackgroundPatient-derived xenografts as in vivo models for research in urological malignancies
Inoue, T., Terada, N., Kobayashi, T., & Ogawa, O. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.19 · Cited by 91
Shukla, S., Cyrta, J., Murphy, D. A., Walczak, E. G., Ran, L., Agrawal, P. K., Xie, Y., Chen, Y., Wang, S., Zhan, Y., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.008 · Cited by 86
“environment, such as by AR mutations, AR splice variants, AR amplification, or aberrant expression of the glucocorticoid receptor (GR) that activates AR target genes (Antonarakis et al., 2014; Arora et al., 2013; Chen et al., 2004; Taplin et al., 1995; Watson et al., 2015).”
SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1
Peacock, J. W., Takeuchi, A., Hayashi, N., Liu, L., Tam, K. J., Nakouzi, N. A., Khazamipour, N., Tombe, T., Dejima, T., Lee, K. C. K., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201707689 · Cited by 83
“Mining of gene expression profiling data from Chen et al (2004) revealed an association between increased SEMA3C expression and resistance to anti-androgen therapy in six out of seven isogenic hormone-sensitive and castration-resistant xenograft pairs [NCBI GEO GDS535 (Barrett et al, 2007)]…”
MethodAndrogen Receptor-Dependent Mechanisms Mediating Drug Resistance in Prostate Cancer
Ehsani, M., David, F. O., & Baniahmad, A. (2021) · Cancers · doi:10.3390/cancers13071534 · Cited by 94
Inoue, T., Segawa, T., Shiraishi, T., Yoshida, T., Toda, Y., Yamada, T., Kinukawa, N., Kinoshita, H., Kamoto, T., & Ogawa, O. (2005) · Urology · doi:10.1016/j.urology.2005.02.028 · Cited by 83
Wako, K., Kawasaki, T., Yamana, K., Suzuki, K., Jiang, S., Umezu, H., Nishiyama, T., Takahashi, K., Hamakubo, T., Kodama, T., et al. (2008) · Journal of Clinical Pathology · doi:10.1136/jcp.2007.050906 · Cited by 83
Ricke, E. A., Williams, K., Lee, Y., Couto, S. S., Wang, Y. Z., Hayward, S. W., Cunha, G. R., & Ricke, W. A. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs153 · Cited by 85
Shiota, M., Yokomizo, A., Tada, Y., Inokuchi, J., Tatsugami, K., Kuroiwa, K., Uchiumi, T., Fujimoto, N., Seki, N., & Naito, S. (2009) · Molecular Endocrinology · doi:10.1210/me.2009-0302 · Cited by 90
He, Y., Xu, Y., Zhang, C., Gao, X., Dykema, K. J., Martin, K. R., Ke, J., Hudson, E. A., Khoo, S. K., Resau, J. H., et al. (2011) · Science Signaling · doi:10.1126/scisignal.2001450 · Cited by 83
Impact of differential cyclin D1 expression and localisation in prostate cancer
Comstock, C. E. S., Revelo, M. P., Buncher, C. R., & Knudsen, K. E. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603615 · Cited by 91
“Restoration of AR activity is known to occur through several discrete pathways, and in model systems of prostate cancer reactivation of AR is causative for therapeutic relapse and tumour recurrence (Chen et al, 2004).”
BackgroundCullin 3 Ubiquitin Ligases in Cancer Biology: Functions and Therapeutic Implications
Chen, H., & Chen, R. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00113 · Cited by 92
“Androgen receptor signaling is crucial for prostate cancer initiation, progression, and development of resistance to antiandrogen therapy (102).”
BackgroundSelf-citationWang, X.-D., Reeves, K., Luo, F. R., Xu, L.-A., Lee, F., Clark, E., & Huang, F. (2007) · Genome Biology · doi:10.1186/gb-2007-8-11-r255 · Cited by 83
“Alteration of the expression or sequence of AR may affect the function of AR in terms of binding to androgen [31] or cross-talk with growth factor and receptor pathways such as phosphorylation of AR by signaling cascades [32].”
BackgroundSteroid hormone synthetic pathways in prostate cancer.
Mostaghel, E. A. (2013) · PubMed · doi:10.3978/j.issn.2223-4683.2013.09.16 · Cited by 80
“Restoration of AR expression and signaling in a xenograft model was both necessary and sufficient to drive progression from androgen-dependent to castration resistant growth, allowing tumor cell proliferation in 80% lower androgen concentrations (22).”
BackgroundPeroxiredoxin 1 Interacts with Androgen Receptor and Enhances Its Transactivation
Park, S.-Y., Yu, X., Ip, C., Mohler, J. L., Bogner, P. N., & Park, Y.-M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0651 · Cited by 80
Direct Regulation of Androgen Receptor Activity by Potent CYP17 Inhibitors in Prostate Cancer Cells
Soifer, H. S., Souleimanian, N. E., Wu, S., Voskresenskiy, A. M., Collak, F. K., Cinar, B., & Stein, C. A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.261933 · Cited by 86
“Although advanced prostate cancers have historically been labeled androgen independent, there is little doubt that the AR still plays a key role in their growth and viability (6, 7).”
Background
Metadata
- Authors
- Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L.
- Affiliations
- University of California, Los Angeles (US)
- Howard Hughes Medical Institute (US)
- University of Washington (US)
- Corresponding author
- Sawyers, Charles L
- Venue
- Nature Medicine
- Published
- 2003-12-21
- Volume
- 10
- Issue
- 1
- Pages
- 33-39
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2003955264
- Cited by
- 2,278
- References
- 50
- Citations by year
- 2026: 21 · 2025: 40 · 2024: 40 · 2023: 72 · 2022: 59 · 2021: 86 · 2020: 68 · 2019: 82 · 2018: 99 · 2017: 110 · 2016: 106 · 2015: 119 · 2014: 128 · 2013: 156 · 2012: 155
- FWCI
- 69.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- prostate cancer, antiandrogen resistance, androgen receptor, castration-resistant prostate cancer, androgen receptor ligand-binding domain, coactivator recruitment, corepressor recruitment, androgen receptor target genes
- MeSH terms
- Androgen Antagonists, Base Sequence, Humans, Male, Prostatic Neoplasms, Receptors, Androgen, DNA Primers, Disease Progression, Antineoplastic Agents, Hormonal, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.